We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2). The antibodies have been tested with COVID-19 positive patient samples.
Limited amounts of R&D samples are available, please inquire below:
See all our COVID-19 Products